SYSTEMIC SCLEROSIS (SSC)

This study tests whether a live attenuated dengue vaccine (Butantan-DV) is safe and works well in people aged 12–59 with autoimmune rheumatic diseases like rheumatoid arthritis or lupus, who are stable on low or no immune-suppressing drugs. Participants receive one shot and are m…

This early-phase study tests a new treatment called HBI0101, which uses a patient's own immune cells modified to target and destroy faulty B cells that cause autoimmune diseases. The study includes up to 120 adults with conditions like lupus, multiple sclerosis, or rheumatoid art…

This study tests an investigational drug called efgartigimod in adults with systemic sclerosis, a disease that causes skin thickening and organ damage. About 81 participants will receive either the drug or a placebo for up to 48 weeks. The main goal is to see if the drug reduces …

This early-phase trial tests a new treatment called zamto-cel for people with severe lupus or scleroderma that hasn't improved with standard therapies. Zamto-cel uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check…

This study tests a new drug called tibulizumab for people with systemic sclerosis, a rare disease that causes skin thickening and can affect internal organs. About 80 adults with moderate to severe skin symptoms will receive either the drug or a placebo for 24 weeks, followed by …

This early-phase study tests a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe autoimmune diseases like scleroderma and Sjogren's syndrome. The goal i…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and whether the treat…

This early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting the immune cells that cause the dama…

This early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…

This early-stage trial tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and side effects, not yet to prove it works. Participants receive the drug by IV and are monitored clos…

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…

This early-stage study tests the safety of a new drug called PRO-203 in 74 people. First, healthy volunteers receive a single injection to check for side effects. Then, people with systemic sclerosis (a chronic autoimmune disease causing skin and organ hardening) receive the drug…

This early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus and rheumatoid arthritis that haven't responded to standard treatments. CC312 works like a 'biological CAR-T' by guiding immune cells to attack and deplete faulty B…

This early-stage study is testing a new treatment called BCMA/CD70 CAR-T for children with severe rheumatic diseases like juvenile dermatomyositis and arthritis that haven't improved with standard therapies. The treatment uses the child's own immune cells, modified in a lab to ta…

This study tests a new treatment called AlloNK, made from donated cord blood cells, combined with the drug rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma) that have not responded to standard therapies. The …

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This early-phase study tests whether a type of immune cell therapy called CAR-T can safely help people with severe systemic sclerosis that hasn't responded to standard treatments. The therapy targets CD19 on immune cells to reduce disease activity. Up to 12 participants aged 5 an…

This early-stage study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The treatment uses a special injection to reprogram the body's own T cells to target and destroy faulty B cells, aim…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-stage study tests a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune s…

This study is testing a new blood test that may help doctors choose the most effective drug for each person with a rheumatic disease like rheumatoid arthritis or lupus. The test looks at how a patient's immune cells react to different medications before treatment starts. The goal…

This study tests an exercise program called BETY in 48 children and adults with scleroderma. The program focuses on physical, mental, and social well-being. Researchers will measure skin tightness, walking ability, and overall quality of life to see if the exercises help reduce s…

This study tests whether a lotion containing 1% hemp extract (CBD) plus 10% urea can reduce itching, improve skin moisture, and help sleep in people with scleroderma. About 36 adults with chronic itching will use both the CBD lotion and a plain urea lotion at different times to c…

This study tests if a person's own fat-derived cells can improve hand function in systemic sclerosis, a disease that causes skin thickening and stiffness. 48 adults with hand problems will either get injections of these cells into their fingers or receive standard care. The goal …

This study tests whether a wearable device called Apollo Neuro can help people with systemic sclerosis feel less tired and have fewer Raynaud's attacks. About 160 adults with the condition will use the device and report their symptoms through a phone app. The goal is to see if th…

This study tests whether injecting sodium thiosulfate directly into painful calcium deposits can shrink them and ease symptoms. It includes 20 adults with systemic sclerosis, dermatomyositis, or mixed connective tissue disease who have calcium buildup in skin or tendons. Particip…

This study tests three different diets to see which one best reduces bloating and other stomach issues in people with systemic sclerosis (scleroderma). Researchers will compare a low-FODMAP diet, a specific elimination diet (CDED), and standard UK dietary advice (NICE). The goal …

This study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…

This study looks at how scleroderma affects physical abilities and daily functioning in both children and adults. Researchers will measure walking, stair climbing, and other activities to understand the challenges patients face. The goal is to find better ways to support disease …

This study looks at how scleroderma affects chewing and swallowing in both children and adults. Researchers will measure things like mouth opening, swallowing ability, and overall well-being. The goal is to find better ways to assess and support patients with these challenges.

This study aims to translate and test a questionnaire called PASTUL, which helps people with scleroderma assess the thickness of their own skin. Researchers will enroll 50 adults with scleroderma to see if the Turkish version is reliable and accurate. The goal is to give patients…

This study aims to find a way to predict serious side effects from cancer immunotherapy, which can make the immune system attack healthy tissues. Researchers will collect blood samples from 300 cancer patients starting immunotherapy and 40 people with autoimmune diseases like lup…

This study aims to develop a better way to measure calcium deposits under the skin in people with scleroderma. Researchers will use CT scans and special software to see if these measurements match how patients report their symptoms. About 56 adults with scleroderma and calcium de…

This study is checking if there is a link between nutrition and how active rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis are. Researchers will measure the nutritional status of 460 participants using different tests and compare it to their disease a…

This study tests whether artificial intelligence (AI) can better detect a serious lung condition called pulmonary arterial hypertension (PAH) in people with scleroderma. PAH often goes unnoticed until it's advanced, but AI might catch it earlier using simple tests like EKGs and e…